Patents by Inventor Kevin Charles Fortner

Kevin Charles Fortner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230391786
    Abstract: The present invention relates to novel cGAS inhibitor compounds, to pharmaceutical compositions comprising the compounds, and to methods of using the compounds and compositions to treat certain pathological conditions.
    Type: Application
    Filed: June 1, 2023
    Publication date: December 7, 2023
    Inventors: Adel AHMED, Christina MARTINEZ BROKAW, Cheryl Ann CARSON, Scott E. CONNER, Kevin Charles FORTNER, Jeffry B. FRANCISKOVICH, Douglas L. GERNERT, Steven J. GREEN, Charles W. LUGAR, III, Jothirajah MARIMUTHU, Shanthi NAGARAJAN, Christodoulos NICOLAOU, Emmanuel ONOBUN, Stephanie Lange STOUT, Eric G. TROMICZAK, Thibault VARIN
  • Publication number: 20230339968
    Abstract: The present invention provides compounds of the formula: where R1, R2, R3, R4, R5, A, B, and Y are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.
    Type: Application
    Filed: June 28, 2023
    Publication date: October 26, 2023
    Inventors: Serge Louis BOULET, Kevin Charles FORTNER, Deqi GUO, David Michael HYMAN, Sheng-Bin PENG, Chong SI
  • Patent number: 11731984
    Abstract: The present invention provides compounds of the formula: where R1, R2, R3, R4, R5, A, B, and Y are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: August 22, 2023
    Assignee: Eli LIlly and Company
    Inventors: Serge Louis Boulet, Kevin Charles Fortner, Deqi Guo, David Michael Hyman, Sheng-Bin Peng, Chong Si
  • Publication number: 20210179633
    Abstract: The present invention provides compounds of the formula: where R1, R2, R3, R4, R5, A, B, and Y are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.
    Type: Application
    Filed: December 4, 2020
    Publication date: June 17, 2021
    Inventors: Serge Louis BOULET, Kevin Charles FORTNER, Deqi GUO, David Michael HYMAN, Sheng-Bin PENG, Chong SI
  • Patent number: 9708297
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: July 18, 2017
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Kevin Charles Fortner, Steven Marc Massey, Jason Kenneth Myers, Antonio Navarro, Miles Goodman Siegel, Russell Dean Stucky
  • Patent number: 9637495
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: May 2, 2017
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Kevin Charles Fortner, Richard Duane Johnston, Steven Marc Massey, Jason Kenneth Myers, Qing Shi, Miles Goodman Siegel
  • Publication number: 20170044138
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 5, 2016
    Publication date: February 16, 2017
    Inventors: David Andrew Coates, Kevin Charles Fortner, Steven Marc Massey, Jason Kenneth Myers, Antonio Navarro, Miles Goodman Siegel, Russell Dean Stucky
  • Publication number: 20170044163
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 5, 2016
    Publication date: February 16, 2017
    Inventors: David Andrew Coates, Kevin Charles Fortner, Richard Duane Johnston, Steven Marc Massey, Jason Kenneth Myers, Qing Shi, Miles Goodman Siegel